[go: up one dir, main page]

NO983438L - Forbedrede konsentrerte injeksjons- og infusjonsl°sninger for intravasal anvendelse - Google Patents

Forbedrede konsentrerte injeksjons- og infusjonsl°sninger for intravasal anvendelse

Info

Publication number
NO983438L
NO983438L NO983438A NO983438A NO983438L NO 983438 L NO983438 L NO 983438L NO 983438 A NO983438 A NO 983438A NO 983438 A NO983438 A NO 983438A NO 983438 L NO983438 L NO 983438L
Authority
NO
Norway
Prior art keywords
infusion solutions
intravasal
concentrated injection
improved concentrated
injection
Prior art date
Application number
NO983438A
Other languages
English (en)
Norwegian (no)
Other versions
NO983438D0 (no
Inventor
Ulrich Speck
Schumann-Giampieri
Peter Muschick
Werner Krause
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO983438D0 publication Critical patent/NO983438D0/no
Publication of NO983438L publication Critical patent/NO983438L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0452—Solutions, e.g. for injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO983438A 1996-01-25 1998-07-24 Forbedrede konsentrerte injeksjons- og infusjonsl°sninger for intravasal anvendelse NO983438L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19604095 1996-01-25
PCT/DE1997/000170 WO1997026862A2 (de) 1996-01-25 1997-01-27 Verbesserte konzentrierte injektions- und infusionslösungen für die intravasale anwendung

Publications (2)

Publication Number Publication Date
NO983438D0 NO983438D0 (no) 1998-07-24
NO983438L true NO983438L (no) 1998-09-18

Family

ID=7784538

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983438A NO983438L (no) 1996-01-25 1998-07-24 Forbedrede konsentrerte injeksjons- og infusjonsl°sninger for intravasal anvendelse

Country Status (21)

Country Link
US (1) US6638913B1 (pt)
EP (1) EP0876140B1 (pt)
JP (1) JP2000505789A (pt)
KR (1) KR100505772B1 (pt)
CN (1) CN1209751A (pt)
AT (1) ATE251893T1 (pt)
AU (1) AU2150497A (pt)
BG (1) BG62913B1 (pt)
BR (1) BR9707081A (pt)
CA (1) CA2244209C (pt)
CZ (1) CZ234898A3 (pt)
DE (2) DE59710863D1 (pt)
DK (1) DK0876140T3 (pt)
ES (1) ES2208884T3 (pt)
HU (1) HUP9901355A3 (pt)
IL (1) IL124676A0 (pt)
NO (1) NO983438L (pt)
PL (1) PL328199A1 (pt)
PT (1) PT876140E (pt)
SK (1) SK101398A3 (pt)
WO (1) WO1997026862A2 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
CA2298475A1 (en) 1997-10-31 1999-05-14 Walter Reed Army Institute Of Research Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
CA2326777C (en) 1998-04-01 2011-12-20 Nortran Pharmaceuticals Inc. Aminocyclohexyl ether compounds and uses thereof
US7524879B2 (en) 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7057053B2 (en) 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
US20020169112A1 (en) * 2001-05-08 2002-11-14 Luc Montagnier Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
ATE325789T1 (de) 2003-05-02 2006-06-15 Cardiome Pharma Corp Aminocyclohexylether-verbindungen und deren verwendung
US7345087B2 (en) 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
CA2561819A1 (en) 2004-04-01 2005-12-01 Cardiome Pharma Corp. Prodrugs of ion channel modulating compounds and uses thereof
US8058304B2 (en) 2004-04-01 2011-11-15 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
JP5583325B2 (ja) 2004-11-08 2014-09-03 カーディオム ファーマ コーポレイション イオンチャネル調節化合物の投与レジメ
US20060270708A1 (en) * 2005-05-25 2006-11-30 Navinta Llc Novel process for preparation of isotonic aqueous injection of ropivacaine
EP1897535A1 (en) * 2006-08-30 2008-03-12 Dirinco AG Substitution fluid for haemofiltration
US20090239894A1 (en) * 2008-03-20 2009-09-24 Bjorn Schurad Stabilized aqueous solutions of ergoline compounds
SG174258A1 (en) 2009-03-06 2011-10-28 Genentech Inc Antibody formulation
US9427186B2 (en) * 2009-12-04 2016-08-30 Endomagnetics Ltd. Magnetic probe apparatus
US10634741B2 (en) 2009-12-04 2020-04-28 Endomagnetics Ltd. Magnetic probe apparatus
PL2542257T3 (pl) 2010-03-01 2018-01-31 Bayer Healthcare Llc Zoptymalizowane przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI)
CN102319258B (zh) * 2011-08-04 2012-10-31 山西诺成制药有限公司 一种5%葡萄糖置换液及其制备方法
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
AU2014229811B2 (en) 2013-03-11 2018-02-15 Endomagnetics Ltd. Hypoosmotic solutions for lymph node detection
US9239314B2 (en) 2013-03-13 2016-01-19 Endomagnetics Ltd. Magnetic detector
US9234877B2 (en) 2013-03-13 2016-01-12 Endomagnetics Ltd. Magnetic detector
WO2014158965A1 (en) * 2013-03-27 2014-10-02 Ge Healthcare As Method and reagent for preparing a diagnostic composition
ES2833377T3 (es) 2015-06-04 2021-06-15 Endomagnetics Ltd Materiales marcadores y formas de localizar un marcador magnético
CN111989121B (zh) * 2018-04-16 2024-08-13 默克专利股份有限公司 高浓缩蛋白质制剂的粘度降低
CN110327292A (zh) * 2019-08-11 2019-10-15 天津乾丰瑞科技有限公司 一种盐酸法舒地尔注射制剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754523A (fr) * 1969-08-06 1971-02-08 Beecham Group Ltd Vaccins
JPS5531068A (en) * 1978-07-04 1980-03-05 Nyegaard & Co As Manufacture of x ray contrast agent injectable sterilized solution
WO1982003773A1 (en) * 1981-04-27 1982-11-11 Baxter Travenol Lab Dialysis solution containing glucose,amino acids & insulin
JPS61502943A (ja) * 1984-06-22 1986-12-18 ビ−チ、リチャ−ド・エル 電解質溶液およびその生体内における使用
IE60901B1 (en) * 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
GB8906130D0 (en) * 1989-03-17 1989-05-04 Nycomed As Compositions
JPH0341033A (ja) * 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
ATE111585T1 (de) 1990-01-18 1994-09-15 Cereria Amos Sgarbi Spa Grablicht.
GB9020091D0 (en) * 1990-09-14 1990-10-24 Nycomed As Contrast media
DE4135193C1 (pt) * 1991-10-22 1993-03-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
IT1256248B (it) * 1992-12-24 1995-11-29 Bracco Spa Formulazioni iniettabili acquose per radiodiagnostica comprendenti miscele di composti aromatici iodurati utili come agenti opacizzanti ai raggi x
WO1995026331A1 (es) * 1994-03-25 1995-10-05 Centro Investigacion Justesa Imagen, S.A. Nuevos dimeros iodados no ionicos como agentes de contraste a los rayos x, metodo para su preparacion y composiciones farmaceuticas que los contienen
DE4446694A1 (de) * 1994-12-09 1996-06-13 Schering Ag Verwendung von Zusätzen zu Kontrastmitteln zur Verbesserung der Bildgebung

Also Published As

Publication number Publication date
HUP9901355A3 (en) 2000-06-28
EP0876140B1 (de) 2003-10-15
KR19990081979A (ko) 1999-11-15
DE59710863D1 (de) 2003-11-20
PL328199A1 (en) 1999-01-18
PT876140E (pt) 2004-02-27
BG102644A (en) 1999-06-30
BR9707081A (pt) 1999-05-25
HUP9901355A2 (hu) 1999-08-30
CN1209751A (zh) 1999-03-03
IL124676A0 (en) 1998-12-06
US6638913B1 (en) 2003-10-28
SK101398A3 (en) 1998-12-02
WO1997026862A2 (de) 1997-07-31
AU2150497A (en) 1997-08-20
WO1997026862A3 (de) 1997-10-23
BG62913B1 (bg) 2000-11-30
JP2000505789A (ja) 2000-05-16
DE19703816A1 (de) 1997-08-07
CA2244209C (en) 2007-10-23
CZ234898A3 (cs) 1998-11-11
NO983438D0 (no) 1998-07-24
DK0876140T3 (da) 2003-12-15
ATE251893T1 (de) 2003-11-15
EP0876140A2 (de) 1998-11-11
KR100505772B1 (ko) 2005-10-25
ES2208884T3 (es) 2004-06-16
CA2244209A1 (en) 1997-07-31

Similar Documents

Publication Publication Date Title
NO983438D0 (no) Forbedrede konsentrerte injeksjons- og infusjonsl°sninger for intravasal anvendelse
EA200200105A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ PPARγ;
ATE413386T1 (de) Ppar-gamma modulatoren
AU1718400A (en) Method for treating pain
PT892780E (pt) Analogos de m-amidino fenilo como inibidores do factor xa
NO993739L (no) Dieseladditiv for aa forbedre cetan, smöreevne og stabilitet
MY133569A (en) Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
AU1676200A (en) Polyhydroxylated heterocyclic derivatives as anti-coagulants
TR200000740T2 (tr) Dişleri beyazlatmak için metod ve kompozisyonlar.
AP9901478A0 (en) Compounds for the treatment of ischemia.
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
PT999750E (pt) Composicao antifungica
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
NO20003758L (no) Trekonserveringsmidler
DE60026350D1 (de) Diaryl piperidyl-pyrrol-derivate als antiprotozoenmittel
DK0896532T3 (da) Acylurinstofforbindelser til behandling af coccidioidomycose i varmblodede dyr
EA199900579A1 (ru) Применение ингибиторов комт для производства лекарственного средства для профилактики сосудистых дисфункций при диабете
DE69409961D1 (de) Triarylethylenderivate zur therapeutischen verwendung
IT9048066A0 (it) 2- amminotetraline-6, 7-sostituite attive come immunomodulanti e composizioni farmaceutiche che le contengono.
MY106261A (en) Anti-inflammatory 1-heteroaryl oxindole-3-carboxamides.
ES2113647T3 (es) Composicion.
EA199900959A1 (ru) Способы снижения содержания фибриногена
ITMI911597A1 (it) Composizione di trattamento di acque di rifiuto da destinare al riciclo, e procedimento di riciclo di acque di rifiuto che utilizza questa composizione.
BG102613A (en) New substituted imidazoles
ID23210A (id) Komposisi sinergistik dan metoda untuk pengobatan neoplastik atau pertumbuhan kanker dan untuk memperbaiki atau meningkatkan hematopoiesis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application